VOR Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Chartmill - Mentions: ALEX TROX CMCT CETX ...

What's going on in today's session

a day ago - By: Chartmill - Mentions: ALEX WHLR CMCT CAL ...

What's going on in today's pre-market session

a day ago - By: Stocktwits - Mentions: JPM

VOR Shares Rally Over 40%In Pre-Market Trade After JPMorgan Initiates Bullish Coverage

a day ago - By: Stocktwits - Mentions: SPY DIA QQQ NVDA ...

Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch

15 days ago - By: Zacks Investment Research

Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know

a month ago - By: Vor Biopharma

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Vor Biopharma

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Benzinga - Mentions: SRDX REAL ENGN SLRX ...

Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump

a month ago - By: Benzinga - Mentions: SRDX SE SLRX OM ...

US Stocks Mixed; Sea Shares Gain After Q3 Results

a month ago - By: Vor Biopharma

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

a month ago - By: Vor Biopharma

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

a month ago - By: Vor Biopharma

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

a month ago - By: Vor Biopharma

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

a month ago - By: Vor Biopharma

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

a month ago - By: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

a month ago - By: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

a month ago - By: Vor Biopharma

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

a month ago - By: Vor Biopharma

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Vor Biopharma

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Vor Biopharma

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

a month ago - By: Vor Biopharma

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

2 months ago - By: Vor Biopharma

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

2 months ago - By: Vor Biopharma

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

2 months ago - By: Vor Biopharma

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

2 months ago - By: Vor Biopharma

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

2 months ago - By: Vor Biopharma

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

2 months ago - By: Vor Biopharma

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

2 months ago - By: Vor Biopharma

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025

VOR BIOPHARMA INC (VOR) Stock News

VOR Latest News, Press Relases and Analysis